Mathieu Richaud

ORCID: 0000-0002-7472-9019
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Axon Guidance and Neuronal Signaling
  • Lung Cancer Research Studies
  • Pancreatic and Hepatic Oncology Research
  • Apelin-related biomedical research
  • Neuroendocrine Tumor Research Advances
  • Hedgehog Signaling Pathway Studies
  • Nuclear Receptors and Signaling
  • Neuroblastoma Research and Treatments
  • HER2/EGFR in Cancer Research
  • Cancer Cells and Metastasis
  • Neurogenesis and neuroplasticity mechanisms

Université Claude Bernard Lyon 1
2021-2025

Centre National de la Recherche Scientifique
2021-2025

Centre Léon Bérard
2021-2025

Inserm
2021-2025

Centre de Recherche en Cancérologie de Lyon
2021-2025

Institut des Sciences Biologiques
2022

Abstract Targeted radionuclide therapy is a revolutionary tool for the treatment of highly spread metastatic cancers. Most current approaches rely on use vectors to deliver radionuclides tumor cells, targeting membrane‐bound cancer‐specific moieties. Here, we report embryonic navigation cue netrin‐1 as an unanticipated target vectorized radiotherapy. While netrin‐1, known be re‐expressed in tumoral cells promote cancer progression, usually characterized diffusible ligand, demonstrate here...

10.15252/emmm.202216732 article EN cc-by EMBO Molecular Medicine 2023-03-06

Small intestinal neuroendocrine tumors (siNETs) are rare bowel arising from malignant enteroendocrine cells, which normally regulate digestion throughout the intestine. Though infrequent, their incidence is rising through better diagnosis, fostering research into origin and treatment. To date, siNETs considered to be a single entity clinically treated as such. Here, by performing multi-omics analysis of siNETs, we unveil four distinct molecular groups with strong clinical relevance provide...

10.1038/s41467-025-57305-8 article EN cc-by-nc-nd Nature Communications 2025-03-04

The navigation cue netrin-1 is well-documented for its key role in cancer development and represents a promising therapeutic target currently under clinical investigation. Phase 1 2 trials are ongoing with NP137, humanized monoclonal antibody against netrin-1. Interestingly, the epitope recognized by NP137 shares 90% homology counterpart netrin-3, closest member to humans, which little known field of cancer. Here, we unveiled that netrin-3 appears be expressed specifically human...

10.15252/emmm.202012878 article EN cc-by EMBO Molecular Medicine 2021-03-15

Abstract Background and Aims Netrin‐1 displays protumoral properties, though the pathological contexts processes involved in its induction remain understudied. The liver is a major model of inflammation‐associated cancer development, leading to HCC. Approach Results A panel cell biology biochemistry approaches (reverse transcription quantitative polymerase chain reaction, reporter assays, run‐on, polysome fractionation, cross linking immunoprecipitation, filter binding assay, subcellular...

10.1002/hep.32446 article EN Hepatology 2022-03-07
Coming Soon ...